<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754156</url>
  </required_header>
  <id_info>
    <org_study_id>07-0694-F2L</org_study_id>
    <nct_id>NCT00754156</nct_id>
  </id_info>
  <brief_title>ABRA Abdominal Closure System in Open Abdomen Management</brief_title>
  <acronym>ABRA</acronym>
  <official_title>A Prospective, Controlled Evaluation of ABRA Abdominal Wall Closure System in Combination With V.A.C. Therapy Compared to V.A.C. Alone in the Management of Open Abdomen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Rockich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the last 20 to 30 years, damage control laparotomy and decompressive laparotomy have
      emerged as part of the armamentariums for treatment of complex abdominal trauma, abdominal
      compartment syndrome, and critically ill surgical patients with profound acidosis. While
      these advances have saved lives, they have also led to a dramatic increase in patients with
      open abdominal cavities. Various methods have been employed to offer protection to the
      viscera and at the same time, encourage gradual closure of the abdominal fascia. Some of the
      techniques have included the Bogota bag, vacuum pack described by Barker , Wittman patch ,
      and the use of vacuum assisted fascia-closure, including the commercially available system
      offered by KCI. Overall, the abdominal closure rate is approximately 50% to 90% over an
      average of 10 days. Unfortunately, there has been no well-designed comparison study
      available. Some of the best results also require returning to the operating room every 3 to 5
      days.

      At the University of Kentucky Medical Center, a combination of the vacuum pack dressing
      described by Barker, the commercially available VAC system (V.A.C.; KCI International, San
      Antonio, TX) and vicryl mesh closure systems are used. The primary fascial closure rate is
      approximately 50%. It is not standard practice to take patients to the OR every 3-5 days
      routinely.

      Recently, a new FDA listed system (ABRA by Canica) has been introduced using a progressive
      tension system as a novel approach to the management of open abdomen. ABRA provides a dynamic
      reduction of full thickness, severely retracted midline abdominal defects with the goal of
      maintaining or restoring the primary closure option. This subdermal method uses button
      anchors and elastomer to gradually pull the wound margins together. Tension can be set and
      adjusted according to the desired outcome; to stabilize a retracted wound, reduce the wound,
      close the wound or prevent wound dehiscence (Attachment 1: Company brochure). Currently there
      is only one published case report of the success of this device. We hope to be the first
      center to prospectively report a series of patients with open abdomen managed with the new
      ABRA system. In this study, this system will be used in combination with a standard therapy
      used in abdominal wound closure at the University of Kentucky Medical Center. This system is
      called the V.A.C system (V.A.C.; KCI International, San Antonio, Tx). This therapy provides
      active exudate management and containment, assists in reducing abdominal volume and adds
      structural stabilization to adipose tissue.

      Although no highly powered study has been done to establish data on performance, individual
      experiences at several institutions have reached fascial closure rates of higher than 70%
      using the ABRA device. One institution in Las Vegas, Nevada is using the ABRA device in
      combination with the VAC system and has experienced 100% closure rate to date with 12
      patients. The purpose of this study is to collect information about the ABRA system in
      combination with the VAC technique at the University of Kentucky Medical Center. It is our
      belief that using this system will improve the fascial closure rate and thereby produce less
      chance of hernia and reduce long periods of open abdominal wounds. The objective of the study
      is to evaluate a novel approach for closure of open abdomen utilizing the Canica ABRA system
      combined with the K.C.I. VAC System to KCI VAC System alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Closure Rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The rate in which the abdomen was closed the first time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Trips to the Operating Room</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Operating Room Time Utilization</measure>
    <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
    <description>The amount of time needed to manage the open abdomen inside the operating room.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to Closure</measure>
    <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Days</measure>
    <time_frame>Duration of hospital stay less than 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Days</measure>
    <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfused</measure>
    <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Open Abdomen</condition>
  <arm_group>
    <arm_group_label>1 ABRA plus KCI ABThera or KCI VAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KCI V.A.C. Therapy or ABThera Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>KCI V.A.C. Therapy ABThera Alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABRA Abdominal Closure System</intervention_name>
    <description>ABRA Abdominal Closure System</description>
    <arm_group_label>KCI V.A.C. Therapy or ABThera Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>V.A.C. Therapy</intervention_name>
    <description>V.A.C. Therapy Alone</description>
    <arm_group_label>1 ABRA plus KCI ABThera or KCI VAC</arm_group_label>
    <arm_group_label>KCI V.A.C. Therapy or ABThera Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KCI ABThera</intervention_name>
    <description>KCI ABThera</description>
    <arm_group_label>1 ABRA plus KCI ABThera or KCI VAC</arm_group_label>
    <arm_group_label>KCI V.A.C. Therapy or ABThera Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ages of 18 and 70

          2. patients deemed not a candidate for primary fascial closure at the second laparotomy.

        Exclusion Criteria:

          1. High risk for imminent death, as determined by the attending surgeon and PI

          2. Pre-existing large ventral hernia

          3. Significant loss of abdominal wall fascia as a result of trauma or infection

          4. Known Crohn's disease

          5. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <results_first_submitted>July 15, 2013</results_first_submitted>
  <results_first_submitted_qc>February 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2014</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Anna Rockich</investigator_full_name>
    <investigator_title>Director, General Surgery Clinical Research Program</investigator_title>
  </responsible_party>
  <keyword>Closure, Wounds</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients who met study criteria were enrolled from January 26, 2009 through December 6, 2010.</recruitment_details>
      <pre_assignment_details>Study candidates were identified following index laparotomy where the abdominal cavity could not be closed primarily. Following informed consent, patients were enrolled if attempts at primary closure were unsuccessful during the second laparotomy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
          <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
        </group>
        <group group_id="P2">
          <title>2 V.A.C. or ABThera Alone</title>
          <description>ABThera V.A.C. Therapy alone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 ABRA Plus V.A.C or ABThera</title>
          <description>ABRA Abdominal Wound Closure System in combination with V.A.C. or AbThera Therapy</description>
        </group>
        <group group_id="B2">
          <title>V.A.C. or ABThera</title>
          <description>V.A.C. or ABThera Therapy alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="12.4"/>
                    <measurement group_id="B2" value="52.8" spread="14.1"/>
                    <measurement group_id="B3" value="51.14" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="5.8"/>
                    <measurement group_id="B2" value="38.0" spread="12.9"/>
                    <measurement group_id="B3" value="30.99" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Base Excess/Base Deficit</title>
          <description>In human physiology, base excess and base deficit refer to an excess or deficit, respectively, in the amount of base present in the blood. The value is usually reported as a concentration in units mmol/L, with a positive number indicating excess of base and a negative deficit. A range for base excess or base deficit is -3 to + 3 mmol/L</description>
          <units>mmole/liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="2.5-18.1" lower_limit="-4.9" upper_limit="19.8"/>
                    <measurement group_id="B2" value="5.1" spread="0.5-9.8" lower_limit="-2.4" upper_limit="15"/>
                    <measurement group_id="B3" value="5.9" lower_limit="-4.9" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APACHE II</title>
          <description>APACHE II (Acute Physiology and Chronic Health Evaluation) scoring system is an objective assessment of severity of illness in patients in the ICU. Scores can range from 0 (low severity) to 71 (high severity).</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.25" spread="9.8"/>
                    <measurement group_id="B2" value="16" spread="11.6"/>
                    <measurement group_id="B3" value="19.00" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Starting Wound Dimension</title>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="575.9" spread="289.2"/>
                    <measurement group_id="B2" value="359.2" spread="245.3"/>
                    <measurement group_id="B3" value="483" spread="75.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trauma</title>
          <description>Number of patients that are trauma patients</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular/Splenectomy/AAA</title>
          <description>Patients who met criteria for entry who had baseline conditions to include vascular issue or splenectomy</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Closure Rate</title>
        <description>The rate in which the abdomen was closed the first time.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Descriptive Study.</population>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 ABThera</title>
            <description>ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Closure Rate</title>
          <description>The rate in which the abdomen was closed the first time.</description>
          <population>Descriptive Study.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Trips to the Operating Room</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with V.A.C or ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 ABThera</title>
            <description>V.A.C. or ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Trips to the Operating Room</title>
          <units>Number of trips</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="3" lower_limit="2.8" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Operating Room Time Utilization</title>
        <description>The amount of time needed to manage the open abdomen inside the operating room.</description>
        <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus V.A.C. or ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with V.A.C. or ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 V.A.C. or ABThera Alone</title>
            <description>V.A.C. or ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Operating Room Time Utilization</title>
          <description>The amount of time needed to manage the open abdomen inside the operating room.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="29"/>
                    <measurement group_id="O2" value="212" spread="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence analysis</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Closure</title>
        <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 V.A.C. or ABThera Alone</title>
            <description>ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Closure</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="4.5" upper_limit="18.0"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.56" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Days</title>
        <time_frame>Duration of hospital stay less than 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 V.A.C. or ABThera Alone</title>
            <description>ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Days</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="12.3" upper_limit="55.0"/>
                    <measurement group_id="O2" value="18" lower_limit="15.0" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Days</title>
        <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 V.A.C. or ABThera Alone</title>
            <description>ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Days</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" lower_limit="22.3" upper_limit="60.8"/>
                    <measurement group_id="O2" value="27.5" lower_limit="25.8" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfused</title>
        <time_frame>Duration of Hospital Stay less than 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
            <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
          </group>
          <group group_id="O2">
            <title>2 V.A.C. or ABThera Alone</title>
            <description>ABThera V.A.C. Therapy alone</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfused</title>
          <units>Units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2650" lower_limit="0" upper_limit="7493"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Hospitalization of enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1 ABRA Plus KCI Abdominal Wound Vac (V.A.C.) or KCI ABThera</title>
          <description>ABRA Abdominal Wound Closure System in combination with ABThera V.A.C. Therapy</description>
        </group>
        <group group_id="E2">
          <title>2 V.A.C. or ABThera Alone</title>
          <description>ABThera V.A.C. Therapy alone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Device failure and skin breakdown</sub_title>
                <description>Mass amount of drainage and infection and absence of wound edge for &gt; 3 days required ABRA removal. Following removal 2 JP drains and wound vac was required. Soft tissue debridement was needed where the ABR button pads rested.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Enterocutaneous Fistula</sub_title>
                <description>This patient developed an entercutaneous fistula during her involvement with the study. She recovered without issue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Limited by small sample size, and lack of closely matched patient groups.
Limited by product change from the original VAC to the ABThera system mid study.
Limited by a significant learning curve in application and use of the ABRA device.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Phillip Chang, M.D. PI or Anna Rockich, Pharm.D. GSRP Director</name_or_title>
      <organization>University of Kentucky Medical Center</organization>
      <phone>859-323-6346 ext 247</phone>
      <email>arockich@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

